Gland Pharma Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Gland Pharma’s Q3 results FY26 are scheduled to be announced on 28th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Gland Pharma Q3 Results 2026 Preview

• Gland Pharma’s revenue is expected to be in the range of ₹1,384.05 crore, a 1.55% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 25.17% YoY. 
• Gland Pharma’s EBITDA is expected to rise to ₹263.63 crore. 
• Net profit is ₹204.69 crore, a rise 25.17% YoY 

Gland Pharma Share Performance 

• Over the past six months, Gland Pharma’s share price has fallen by 18.90% to ₹1,664.40.
• Moreover, over the past year, the stock has increased by 15.57%.
• Despite this weak short-term performance, Gland Pharma’s stock has delivered a financially sound 21.35% return over the past 5 years.
• As of 27th January 2026, the stock traded at ₹1,664.40 per share.

Key Factors to Watch for Gland Pharma Q3 Results FY26 

• Revenue & geographic mix – Growth or contraction in total sales, especially performance in key markets like the US, Europe and India.
• Profitability & margins – Trends in PAT, EBITDA and operating margins showing cost management and business strength.
• Cenexi CDMO performance & integration – Progress and profitability of the Cenexi contract development & manufacturing arm.
• Product launches & ANDA filings – New product approvals, ANDA filings and pipeline expansion supporting future growth.
• Regulatory/quality developments – USFDA inspection outcomes and compliance milestones influencing exports and market access.

Final Thoughts

Gland Pharma will announce its Q3 FY26 results on 28th January 2026. Analysts expect 1.55% YoY revenue growth, a 25.17% rise in PAT, and a 29.72% rise in EBITDA. Gland Pharma focuses on expanding global revenues through new product launches, CDMO growth, and maintaining regulatory compliance to support margins.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Gland Pharmaelerator IPO GMP & Review: Apply or Avoid?

Vigor Plast India IPO Listing Preview: What to Expect Now?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates